Clinical Trial Update: Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial of bortezomib plus vorinostat in younger patients with MLL-rearranged hematologic malignancies was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Mixed Lineage Leukemia

Drugs mentioned

• Velcade (bortezomib)
• Zolinza (vorinostat)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2018-02-01